Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer

Chundong Cheng1,2 | Danxi Liu1,2 | Zonglin Liu1,2 | Mengyang Li3 | Yongwei Wang1,2 | Bei Sun1,2 | Rui Kong1,2 | Hua Chen1,2 | Gang Wang1,2 | Le Li1,2 | Jisheng Hu1,2 | Yilong Li1,2 | Hongze Chen1,2 | Zhongjie Zhao1,2 | Tao Zhang1,2 | Siqiang Zhu1,2 | Shangha Pan1,2

1Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
2Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Harbin, China
3Department of Medical Oncology, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Correspondence
Yongwei Wang and Bei Sun, Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin 150001, Heilongjiang, China.
Emails: wangyongwei163@163.com (Y.W.); sunbei70@tom.com (B.S.)

Funding information
This work was supported by the Excellent Young Medical Talents Training Fund of the First Affiliated Hospital of Harbin Medical University (HYD2020YQ0010), National Nature Scientific Foundation of China (81702384, 81372613, 81670583, and 81800572), Heilongjiang Postdoctoral Scientific Research Developmental Fund (LBH-Q20142), and Innovative Young Talents Training Scheme for General Undergraduate Higher Education Institutions in Heilongjiang (UNPYSCT-2016188).

Abstract
Emerging evidence has indicated that long noncoding RNAs (lncRNAs) are potential biomarkers and play crucial roles in cancer development. However, the functions and underlying mechanisms of lncRNA TPT1-AS1 in pancreatic ductal adenocarcinoma (PDAC) remain elusive. RNAseq data of PDAC tissues and normal tissues were analyzed, and lncRNAs which were associated with PDAC prognosis were identified. The clinical relevance of TPT1-AS1 for PDAC patients was explored, and the effects of TPT1-AS1 in PDAC progression were investigated in vitro and in vivo. LncRNA TPT1-AS1 was highly expressed in PDAC, and high TPT1-AS1 levels predicted a poor prognosis. Moreover, functional experiments revealed that TPT1-AS1 promoted pancreatic cancer cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) process in vitro and in vivo. Mechanistically, TPT1-AS1 functioned as an endogenous sponge for miR-30a-5p, which increased integrin β3 (ITGB3) level in pancreatic cancer cells. Conversely, our data revealed that ITGB3 could activate the transcription factor signal transducer and activator of transcription 3 (STAT3), which in turn bound directly to the TPT1-AS1 promoter and affected the expression of TPT1-AS1, thus forming a positive feedback loop with TPT1-AS1. Taken together, our results uncovered a reciprocal loop of TPT1-AS1 and ITGB3 which contributed to pancreatic cancer growth and development, and indicated that TPT1-AS1 might serve as a novel potential diagnostic biomarker and therapeutic target for PDAC patients.

KEYWORDS
ITGB3, miR-30a-5p, pancreatic cancer, STAT3, TPT1-AS1

Abbreviations: cDNA, complementary DNA; ceRNA, competing endogenous RNA; EdU, 5-ethyl-2-deoxyuridine; EMT, epithelial-mesenchymal transition; IHC, immunohistochemistry; ITGB3, integrin β3; lncRNAs, long noncoding RNAs; miRNAs, microRNAs; MUT, mutant-TPT1-AS1; PDAC, pancreatic ductal adenocarcinoma; qRT-PCR, real-time quantitative reverse-transcription polymerase chain reaction; si-NC, siRNA-negative control; siRNA, small interfering RNA; STAT3, signal transducer and activator of transcription 3.

Chundong Cheng, Danxi Liu, and Zonglin Liu contributed equally.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
1 | BACKGROUND

Pancreatic ductal adenocarcinoma (PDAC) accounts for 3% of all new cancer diagnoses and 7.5% of all cancer deaths in the United States. The 5-year overall survival rate for all types of cancers has exceeded 60%; however, PDAC is still one of the most aggressive and lethal malignancies. The 5-year survival rate is less than 9%. The high mortality rate of PDAC patients is due to the absence of grave symptoms coupled with the unavailability of early prognostic and diagnostic markers and resistance to chemo- and radio-therapies. Therefore, there is an urgent need to search for biomarkers which can effectively predict the prognosis of PDAC and develop efficient therapeutic approaches.

Accumulating evidence has shown that aberrant noncoding RNAs including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) play key roles in diverse biological processes, including proliferation, motility, immortality, viability, and angiogenesis. IncRNAs exert their biological functions in regulating tumor progression through multiple mechanisms. Recent studies have revealed that IncRNAs could act as competing endogenous RNA (ceRNA) through their miRNAs’ pairing sites, which restore the post-transcriptional repression of messenger RNAs (mRNAs) by competing with miRNAs. Aberrant regulation of IncRNAs has been identified in gastric, colorectal, and hepatocellular carcinoma as well as PDAC, which affects cell proliferation, migration, and invasion through ceRNA mechanisms. To the best of our knowledge, although some aberrant IncRNAs play key roles in the initiation and development of pancreatic cancer, more research is needed to elucidate the underlying mechanisms of IncRNAs in pancreatic cancer.

In this study, we found that the elevated expression of TPT1-AS1 led to a poor prognosis for pancreatic cancer patients. TPT1-AS1 promoted pancreatic cancer cell proliferation, migration, invasion, and EMT process in vitro and in vivo. Mechanistically, TPT1-AS1 promoted the expression of its target gene ITGB3 by sponging miR-30a-5p. Conversely, ITGB3 could promote TPT1-AS1 transcription by activating signal transducer and the activator of transcription 3 (STAT3) which bound to the TPT1-AS1 promoter region, thus forming a positive feedback circuit. In summary, we propose a positive feedback loop of TPT1-AS1/miR-30a-5p/ITGB3/STAT3 in pancreatic cancer, providing a new prognostic biomarker and therapeutic target for PDAC patients.

2 | MATERIALS AND METHODS

2.1 | Patients and specimens

Human PDAC specimens were collected from 69 patients with PDAC who underwent pancreatectomy in the Department of Pancreatic and Biliary Surgery (The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China) from January 2009 to January 2018 (Table 1). The study was approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University. Every patient gave written informed consent before participating in this study. Fresh tissues were immediately frozen in liquid nitrogen and preserved at −80°C before use.

2.2 | RNA extraction and quantitative real-time PCR analysis

Total RNA was extracted and isolated from the cell lines and frozen tumor specimens using an AxyPrep Multisource Total RNA Miniprep Kit from Axygen (Coring), and the first strand of cDNA was synthesized using Rever TraAce qPCR RT Kit Master Mix with gDNA Remover (FSG-101, Toyobo Co. Ltd.) according to the manufacturer instructions. Quantitative PCR assays were carried out on a 7500 FAST Real-Time PCR System (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and U6 small nuclear RNA (snRNA) were used as endogenous controls for lncRNA, mRNA, and miRNA. The expression levels of RNA were calculated using the 2 −ΔΔT method after normalization to the expression of the control. The primer sequences are described in Additional file 1: Table S1.

2.3 | Cell transfection and viral infection

siRNA for TPT1-AS1 and ITGB3 (si-TPT1-AS1, si-ITGB3), si-NC, miRNA mimics, control mimics, miRNA inhibitors, and control inhibitors were purchased from RiboBio. Human TPT1-AS1 and ITGB3 cDNA were cloned into a plasmid (GeneCopeia) to overexpress TPT1-AS1 and ITGB3. Cell infection was performed using 50 nM siRNA or plasmids with Lipofectamine 2000 (Life Technologies Limited). To establish stable transfectants with knockdown or overexpression, lentiviruses with scrambled short hairpin RNA (shRNA) against TPT1-AS1 (shTPT1-AS1) and the shRNA control (shCtrl) were constructed in GV112 (GeneChem). Lentiviral vectors encoding human TPT1-AS1 (TPT1-AS1) and empty vectors were constructed in GV112 (GeneChem).
2.4 | Cell-counting kit (CCK-8) assay and colony assay

A CCK-8 (Dojindo) was used to assess cell proliferation according to the protocols of the manufacturer. Briefly, 2000 cells were seeded into 96-well plates. Ten microliters of CCK-8 solution was added to each well of cells. After 2 hours of incubation, the absorbance in each well was measured at 24, 48, 72, and 96 hours. In the colony formation experiment, 1000 cells transfected with pcDNA-TPT1-AS1, si-TPT1-AS1, and negative control were seeded in six-well plates. The colonies were fixed with methanol for 30 minutes and stained in 1% crystal violet after 2 weeks.

2.5 | EdU proliferation assay

EdU assay (RiboBio) was performed to measure cell proliferation. After transfection, 10,000 infected cells were seeded in 96-well plates, and then the cells were treated following the manufacturer’s instructions.

2.6 | Luciferase reporter assay

Full-length MUT was amplified and cloned into the pmir-Report luciferase vector (GenScript). According to the predicted binding site of TPT1-AS1 and miR-30a-5p, the sequence of the binding site was mutated to CACCGT. Then, 50 nm miR-30a-5p mimic and 500 ng of luciferase constructs were cotransfected into PANC-1 cells, and 100 nm miR-30a-5p inhibitor and 500 ng of luciferase constructs were cotransfected into BxPC-3 cells according to the manufacturer’s instructions. The luciferase activities were measured with the Dual-Luciferase Reporter Assay System (Promega) after 24 hours transfection using a Varioskan Flash Spectral Scanning Multimode Reader (Thermo Fisher Scientific) according to the manufacturer’s instructions. Firefly luciferase activity was used to normalize the transfection efficiency. For examining the binding between ITGB3 and miR-30a-5p, ITGB3-WT or ITGB3-MUT luciferase reporter was built to perform similar procedures. The plasmids that inserted four fragments of the promoter (P1, P2, P3, and P4) in front of the luciferase sequence were built to explore which fragments of the promoter could bind to STAT3.

2.7 | RNA-binding protein immunoprecipitation (RIP)

RNA-binding protein immunoprecipitation assays were performed to validate the interaction of TPT1-AS1 with miR-30a-5p. The Magna RIP RNA-binding Protein Immunoprecipitation Kit was used to conduct the RIP assay. Cells were lysed with 500 µl of lysis buffer for 20 minutes on ice. Cell lysates (500 µl) with 5 µg of isotype control IgG (Cell Signaling Technology) and anti-Ago2 antibody (Abcam) were incubated overnight at 4°C. Then, to digest the proteins, proteinase K was incubated in the samples. The supernatant was collected for RNA isolation using TRIzol Ls Reagent (Thermo Scientific) and was used for qRT-PCR analysis.

**FIGURE 1** lncRNA TPT1-AS1 is overexpressed and associated with poor clinical outcome in pancreatic ductal adenocarcinoma (PDAC). (A, B) Heatmap and volcano plots showing the differentially expressed lncRNAs in five pairs of PDAC and normal pancreatic tissues (fold change ≥2, p < 0.05). (C) The relative expression of TPT1-AS1 in pancreatic cancer tissues and normal pancreatic tissues in GSE62452. (D, E) The relative expressions of TPT1-AS1 in PDAC with different TNM stages and pathological stages were detected by qRT-PCR. (F) Kaplan-Meier analysis of the survival rate of pancreatic cancer patients based on high TPT1-AS1 levels and low TPT1-AS1 levels in our cohort (n = 69, p = 0.0096). (G) Relative expression of TPT1-AS1 in pancreatic cancer cell lines were detected by qRT-PCR. *p < 0.05, **p < 0.01, ***p < 0.001
FIGURE 2  TPT1-AS1 promotes pancreatic cancer cell proliferation in vitro and in vivo. (A) The functions of TPT1-AS1 knockdown on proliferation were measured by EdU assays in CFPAC-1 and PANC-1 cells. (B) The functions of TPT1-AS1 overexpression on proliferation were measured by EdU assays in BxPC-3 and SW1990 cells (original magnification, 20×). (C–H) Representative bioluminescence imaging (following intraperitoneal injection of 0.1 mg/g luciferin) of mice on days 7, 14, 21, and 28. On day 28, all mice were sacrificed, the primary tumors were removed, and tumor volume and weight were evaluated. Statistical significance between different groups was calculated with Student’s t test. Data are shown as mean ± SD of three replicates; *p < 0.05, **p < 0.01, ***p < 0.001.
FIGURE 3  TPT1-AS1 promotes pancreatic cancer cell migration, invasion, and epithelial-mesenchymal transition (EMT). (A, B) The functions of TPT1-AS1 knockdown or overexpression on metastasis were assessed by Transwell assays (original magnification, 20×). (C, D) The expression of E-cadherin, N-cadherin, and vimentin were measured by Western blot assays after TPT1-AS1 knockdown or overexpression. (E, F) The expression of E-cadherin, N-cadherin, vimentin, and Ki-67 were analyzed in paraffin-embedded tissue sections of orthotopic pancreatic cancer models from different groups by immunohistochemistry (original magnification, 20×; bar, 400 μm). Statistical significance between different groups was calculated with Student's t test. Data are shown as mean ± SD of three replicates; *p < 0.05, **p < 0.01, ***p < 0.001.
2.8 | Orthotopic tumor model

The animal studies were approved by the Institutional Review Board of the First Affiliated Hospital of Harbin Medical University. CFPAC-1-shTPT1-AS1, BxPC-3-TPT1-AS1, and their control cells expressing luciferase were injected into the flanks of nude mice. Then, 1-mm³ pieces of tumor harvested from four mice were translocated into four groups of mouse pancreatic tails. The animals were imaged weekly using the Night OWL II LB983 imaging system in vivo (Berthold Technologies GmbH & Co. KG). The primary and metastatic pancreatic tumors were excised, weighed, and fixed in 4% paraformaldehyde.

2.9 | Immunohistochemical staining

The paraffin-embedded tissue sections were immunostained with anti-N-cadherin, anti-E-cadherin, vimentin, ITGB3, and anti-Ki-67. The number of positive cells was counted in five randomly selected microscopic fields (×20, Nikon). The primary antibodies for IHC are listed in Additional file 2: Table S2.

The materials and methods of cell culture, Western blot assay, Transwell assay, and wound healing assay are listed in Additional file: additional material and methods.

2.10 | Statistical analysis

Statistical analysis was performed with SPSS 19.0 software or GraphPad Prism 7.0 software. The data are shown as the mean ± SD. Pearson analysis, Kaplan-Meier survival analysis, one-way ANOVA, and Student’s t test were used to evaluate the statistical significance.

3 | RESULTS

3.1 | High TPT1-AS1 levels are correlated with poor clinical outcomes

A genome-wide analysis of five pairs of PDAC tissues and normal pancreatic tissues was performed to explore the relationship between IncRNA expression and pancreatic cancer properties. We found 39 differentially expressed IncRNAs (fold change ≥2 and p < 0.05), including 20 upregulated and 19 downregulated genes, of which TPT1-AS1 was one of the top upregulated IncRNAs in PDAC (Figure 1A,B). TPT1-AS1 had been shown to promote tumor progression in different models, including, for example, colorectal cancer, ovarian cancer, and gastric cancer. However, the specific role of TPT1-AS1 in PDAC remains elusive. Therefore, to investigate the roles of TPT1-AS1 in PDAC, we first compared the levels of TPT1-AS1 in normal pancreatic tissue and PDAC tissue in the GEO dataset (GSE62452) and found that TPT1-AS1 was highly expressed in pancreatic cancer tissues compared with normal tissues (Figure 1C). Furthermore, the expression of TPT1-AS1 in 69 PDAC tissues was evaluated. Our results showed that the level of TPT1-AS1 was significantly increased in advanced pancreatic cancer compared with that in early stage (Figure 1D). Meanwhile, we detected that the level of TPT1-AS1 in poorly differentiated pancreatic cancer tissues was significantly upregulated compared with that in highly differentiated tissues (Figure 1E). Furthermore, Kaplan-Meier analysis revealed that PDAC patients with high TPT1-AS1 levels had a poorer prognosis than those with low TPT1-AS1 levels (Figure 1F).

We analyzed the relationship between TPT1-AS1 and clinical characteristics and discovered that the expression levels of TPT1-AS1 were significantly correlated with TNM stage (p = 0.016) and tumor differentiation (p = 0.041) (Table 1). Moreover, the expression levels of TPT1-AS1 were increased in pancreatic cancer cell lines compared with normal human pancreatic duct epithelial (HPDE) cell lines (Figure 1G). Taken together, these data demonstrated that TPT1-AS1 played an oncogenic role and was correlated with tumor progression in pancreatic cancer.

3.2 | TPT1-AS1 promotes pancreatic cancer proliferation

To explore the proliferative function of TPT1-AS1 in pancreatic cancer cells, siRNA (si-TPT1-AS1) and overexpression plasmids (pcDNA-TPT1-AS1) were transfected into pancreatic cancer cell lines. The efficiency of siRNA, plasmid, and lentiviruses were tested by qRT-PCR (Figure S1A–D). The results of CCK-8 assays (Figure S2A) and EdU assays (Figure 2A) indicated that TPT1-AS1 knockdown significantly inhibited cell proliferation and blocked...
DNA replication in pancreatic cancer cells. Consistently, colony formation assays demonstrated that inhibition of TPT1-AS1 decreased pancreatic cancer cell colony formation (Figure S3A). In contrast, TPT1-AS1 overexpression had the opposite effects in pancreatic cancer cells (Figure 2B, Figures S2B and S3B).

To explore the role of TPT1-AS1 in vivo, a pancreatic orthotopic tumor model was used to assess the effect of TPT1-AS1 in tumor proliferation. As shown in Figure 2C–H, TPT1-AS1 overexpression increased tumor size, and TPT1-AS1 knockdown reduced tumor growth, which was consistent with the experimental data in vitro,
suggesting that TPT1-AS1 promoted pancreatic cancer cell proliferation in vitro and in vivo.

### 3.3 | TPT1-AS1 promotes migration, invasion, and EMT in pancreatic cancer

Next, to assess the effect of TPT1-AS1 on cancer cell migration and invasion, Transwell and wound-healing assays were conducted. Our results demonstrated that inhibition of TPT1-AS1 suppressed pancreatic cancer cell migration and invasion (Figure 3A, Figure S4A). Similarly, TPT1-AS1 overexpression had the opposite effects on migration and invasion (Figure 3B, Figure S4B). Epithelial-mesenchymal transition has been recognized as a key regulator of metastasis of cancers, therefore, we then investigated the effects of TPT1-AS1 on the EMT process. Our data demonstrated that TPT1-AS1 overexpression decreased the expression of epithelial marker E-cadherin and increased the levels of the mesenchymal marker N-cadherin and vimentin (Figure 3D, Figure S5B). On the contrary, TPT1-AS1 knockdown showed opposite effects (Figure 3C, Figure S5A). Additionally, Ki-67, a key regulatory gene in cell proliferation, is a marker of proliferation to measure proliferation activity in tissues. Immunohistochemical results of showed a higher rate of Ki-67, N-cadherin, vimentin positivity, and E-cadherin negativity in pancreatic orthotopic tumors built with overexpressed TPT1-AS1 BxPC-3 cells (Figure 3F). The opposite results were displayed in tumors built with TPT1-AS1 knockdown CFPAC-1 cells (Figure 3E). Based on the results, we demonstrated that TPT1-AS1 promoted pancreatic cancer cell proliferation, migration, and invasion in vitro and in vivo.

### 3.4 | TPT1-AS1 acts as a sponge for miR-30a-5p in pancreatic cancer cells

IncRNAs have been shown to act as ceRNAs and sponge miRNAs to suppress target gene expression. To determine the molecular mechanism by which TPT1-AS1 promotes proliferation, migration, invasion, and EMT process in pancreatic cancer, we first used the IncRNA subcellular localization predictor (IncLocator, http://www.csbio.sjtu.edu.cn/bioinf/IncLocator) to predict its location in pancreatic cancer cells (Figure 4A). Furthermore, FISH assays showed that TPT1-AS1 was predominantly located in the cytoplasm (Figure 4B). Both of the results indicated that TPT1-AS1 was mainly distributed in the cytoplasm, which suggested that TPT1-AS1 might regulate downstream protein expression via a post-transcriptional regulatory mechanism. To explore the ceRNA network induced by TPT1-AS1, differential miRNAs in pancreatic cancer tissues (n = 3) and normal pancreatic tissues (n = 3), including 34 upregulated and 27 downregulated genes, were identified (Figure 4C). Furthermore, StarBase v2.0 was used to predict the potential interaction between miRNA and TPT1-AS1. We found that miR-30a-5p, which was predicted through Venn diagram, was the only intersected gene (Figure 4D, Figure S6A). In our study, we found that miR-30a-5p expression in PDAC tissues was lower than that in normal tissues in the GEO database (GSE24279) (Figure 4E). Our results showed that miR-30a-5p was substantially downregulated in PDAC patients (Figure 4F), and an obvious negative association between TPT1-AS1 and miR-30a-5p expression was observed in PDAC tissues (Figure 4G). To examine the relationship between TPT1-AS1 and miR-30a-5p, we examined miR-30a-5p expression after altering TPT1-AS1 expression. TPT1-AS1 knockdown increased the expression of miR-30a-5p (Figure S6B), whereas TPT1-AS1 overexpression decreased miR-30a-5p expression (Figure S6C). Additionally, the interrelationship between miR-30a-5p and TPT1-AS1 was verified by luciferase assays, indicating that miR-30a-5p overexpression significantly inhibited luciferase activity (Figure 4H) and miR-30a-5p knockdown promoted luciferase activity. (Figure 4I). It is widely accepted that Ago2, a main component of the RNA-induced silencing complex, plays an important role in the miRNA-mediated repression of mRNA. The results of RIP assays confirmed that TPT1-AS1 could bind to the Ago2 protein (Figure 4J). In order to investigate the direct interaction between TPT1-AS1, miR-30a-5p, and Ago2, miR-mimics were transfected into CFPAC-1 cells. RNA-binding protein immunoprecipitation assay showed that higher abundance of TPT1-AS1 was precipitated with Ago2 when tumor cells were transfected with miR-mimics (Figure S6D). These results indicate that TPT1-AS1 acts as a sponge for miR-30a-5p in pancreatic cancer cells.

### 3.5 | TPT1-AS1 facilitates tumorigenesis through inhibiting miR-30a-5p

To investigate the roles of miR-30a-5p in PDAC, miR-30a-5p mimics or inhibitors were transfected into pancreatic cancer cells (Figure S6E,F). Our data indicated that miR-30a-5p overexpression significantly inhibited cell proliferation (Figure S7A,C,E) migration,
Invasion (Figure S8A,C), and EMT process (Figure S9A). In contrast, miR-30a-5p knockdown increased pancreatic cancer cell proliferation (Figure S7B,D,F), migration, invasion (Figure S8B,D), and EMT process (Figure S9B). To investigate the roles of miR-30a-5p on TPT1-AS1-induced tumor progression, miR-30a-5p inhibitors and mimics were transfected into pancreatic cancer cells with TPT1-AS1 depletion (Figure S10A,B). Our results showed that miR-30a-5p knockdown was found to restore the suppressive effects of TPT1-AS1 knockdown on pancreatic cancer cell proliferation (Figure 5A, Figure S10C,D, Figure S11A), migration, invasion (Figure 5C,D,E, 5F, Figure S10C,D, Figure S11A).
miR-30a-5p. Moreover, according to the results of qRT-PCR assays, miR-30a-5p overexpression inhibited the effects of TPT1-AS1 on pancreatic cancer cell proliferation (Figure 5B, Figure S10F, Figure S11B), migration, invasion (Figure 5F,G,H, Figure S12B), and EMT process (Figure 5J, Figure S13B). The results suggested that TPT1-AS1 promoted pancreatic cancer cell proliferation, migration, invasion, and EMT process by competitively binding with miR-30a-5p.

3.6 | Silencing ITGB3 reverses the effect of promoting carcinogenesis induced by TPT1-AS1

It is well known that miRNAs induce mRNA degradation by binding to the 3’ untranslated region (3’ UTR). To explore the candidate target for miR-30a-5p, differential mRNAs in PDAC tissues (n = 5) and normal pancreatic tissues (n = 5) were identified (Figure 6A,B). TargetScan, miRtarbase, and differential mRNAs from genome-wide analysis were analyzed through Venn diagram (Figure 6C). According to Starbase v3.0 (http://starbase.sysu.edu.cn/index.php), ITGB3 has a presumed binding site for the seed sequence of miR-30a-5p (Figure 6D). According to the GEPIA program, ITGB3 was highly expressed in pancreatic cancer tissues (Figure 6E) and was strongly associated with patient survival (Figure 6F) and disease-free survival (Figure S14A). We also found that TPT1-AS1 was positively correlated with ITGB3 (Figure 6G). In our cohort research, we found a negative correlation between miR-30a-5p and ITGB3 (Figure 6H) and a positive correlation between TPT1-AS1 and ITGB3 (Figure 6I). Our data showed that miR-30a-5p inhibitors significantly increased the luciferase activity of ITGB3-WT (Figure 6J) and miR-30a-5p mimics inhibited the luciferase activity of ITGB3-WT (Figure 6K), while the reporter containing mutant sites did not respond to either miR-30a-5p overexpression or knockdown. These findings indicated that ITGB3 was a downstream target of miR-30a-5p. Moreover, according to the results of qRT-PCR assays (Figure S14B) and Western blot (Figure S14C,D), TPT1-AS1 overexpression increased the expression of ITGB3, and TPT1-AS1 knockdown decreased the expression of ITGB3. In addition, the mRNA and protein expression levels of ITGB3 were significantly decreased in the miR-30a-5p mimics group and increased in the miR-30a-5p inhibitors group (Figure 6L–P), which indicated that miR-30a-5p could target ITGB3 and inhibited its expression. Furthermore, IHC analysis showed that ITGB3 protein was higher in the high-TPT1-AS1 group (Figure 6Q). Moreover, transfection with miR-30a-5p inhibitors eliminated the decrease in ITGB3 expression levels in TPT1-AS1–knockdown pancreatic cancer cells (Figure S14E,G). Opposite results of Western blot were obtained in TPT1-AS1–overexpressed pancreatic cancer cells (Figure S14F,H). We then explored whether TPT1-AS1 increased carcinogenesis through elevating ITGB3. The results showed that ITGB3 overexpression reversed the inhibitory effects on proliferation (Figure 7A, Figure S15A,B, Figure S16A), migration, invasion (Figure 7C,D,E, Figure S17A), and EMT process (Figure 7J, Figure S18A) induced by shTPT1-AS1. The same results of cell proliferation (Figure 7B, Figures S15C,D and Figure S16B), migration, invasion (Figure 7F,G,H, Figure S17B), and EMT process (Figure 7I, Figure S18B) were obtained in BxPC-3 and SW1990. Taken together, our results revealed that TPT1-AS1 might act as a ceRNA to regulate ITGB3 expression through sponging miR-30a-5p and plays an oncogenic role in pancreatic cancer.

3.7 | ITGB3 elevated TPT1-AS1 expression through enhancing STAT3 in pancreatic cancer cells

Transcription factors have been reported to be engaged in regulating IncRNA expression.29 In our study, we found that ITGB3 knockdown decreased the expression of TPT1-AS1. In contrast, overexpressing ITGB3 increased the expression of TPT1-AS1 (Figure 8A). Previous studies have reported that ITGB3 can induce STAT3 activation.30 We then detected the expression of STAT3 and phosphorylation of STAT3 (p-STAT3) in ITGB3-knockdown or -overexpression pancreatic cancer cells. Our results demonstrated that ITGB3 enhanced p-STAT3 (Figure 8B, Figure S19A). STAT3 is a transcription factor which could participate in modulating IncRNAs expression.15,31,32 The online bioinformatics tool JASPAR (http://jaspar.genereg.net) was used to explore the relationship between STAT3 and TPT1-AS1 (Figure 8C). Four major binding sites on the promoter region of TPT1-AS1 were predicted.
CHENG Et al. (Figure 8D), and the plasmids that inserted four fragments of the promoter (P1, P2, P3, and P4) in the front of the luciferase sequence were built to explore which fragments of the promoter could bind to STAT3. The dual luciferase assays showed that luciferase activity was increased when we transfected the plasmid containing the P2 fragment (Figure 8E). Previous literature
reported that IL-6 could promote tumor progression by activating STAT3; consistently, we found that upregulation of IL-6–activated STAT3 increased TPT1-AS1 expression in pancreatic cancer cells (Figure S19B). In summary, ITGB3 upregulated the transcription of TPT1-AS1 by activating STAT3, which could form a positive feedback loop to enhance the expression of TPT1-AS1.

4 | DISCUSSION

Numerous lncRNAs have been identified by human transcriptome sequencing, and an increasing number of studies have shown that plenty of cancer-associated lncRNAs play important roles in regulating tumorigenesis and progression.33–38 Therefore, lncRNAs can serve as a valuable class of biomarkers and potential therapeutic targets. In this study, we identified a PDAC-related lncRNA, TPT1-AS1, by genome-wide analysis, which was significantly overexpressed in PDAC tissues and cell lines compared with normal pancreatic tissues and normal pancreatic ductal epithelial cell lines, respectively. Besides, high expression of TPT1-AS1 was positively correlated with advanced TNM stage and poor differentiation, indicating a poor clinical prognosis of PDAC patients. In addition, previous research showed that TPT1-AS1 functioned as an oncogene in gastric cancer, colorectal cancer, ovarian cancer, cervical cancer, among others.16–19,39,40 Moreover, functional experiments revealed that TPT1-AS1 could promote pancreatic cancer cell proliferation, invasion, migration, and EMT process in vitro and in vivo. These findings were consistent with those of previous studies and suggested that TPT1-AS1 acted as an oncogenic lncRNA in PDAC.

In previous studies, tumor protein, translationally controlled tumor protein 1 (TPT1), located at the opposite strand of TPT1-AS1, is a regulator of cellular growth and proliferation. TPT1 is known as a tumor oncogene in many cancers, such as ovarian cancer and pancreatic cancer.17,41 In our study, we found that TPT1-AS1 positively regulates the expression of TPT1.

Increasing researches has demonstrated that lncRNAs can function as ceRNAs, which can promote mRNA expression by competitively binding to miRNAs.31,42,43 The biological functions performed by lncRNAs are mainly dependent on their subcellular localization, and several studies have revealed that lncRNAs located in the cytoplasm could participate in gene regulation at the post-transcriptional level, including but not limited to act as ceRNAs to protect the mRNAs from repression. By using bioinformatics databases and FISH assays, we demonstrated that TPT1-AS1 mainly located in the cytoplasm, indicating that it had the potential to function as a miRNA sponge. Our results showed that miR-30a-5p was substantially downregulated in PDAC patients, and a negative correlation between TPT1-AS1 and miR-30a-5p expression was confirmed in PDAC tissues in our cohort and GSE24279 database. Further, TPT1-AS1 knockdown increased the expression of miR-30a-5p, whereas TPT1-AS1 overexpression decreased miR-30a-5p expression. Importantly, the following luciferase reporter and RIP assays indicated that TPT1-AS1 acted as a sponge for miR-30a-5p by directly binding to a complementary sequence in pancreatic cancer cells. miR-30a-5p has been thoroughly shown to serve as a tumor suppressor in many cancers.44–50

In our study, miR-30a-5p overexpression inhibited pancreatic cancer proliferation, migration, invasion, and EMT process. The rescue experiments revealed that miR-30a-5p overexpression partially reversed the TPT1-AS1 overexpression–mediated oncogenic effects. In contrast, miR-30a-5p knockdown led to the opposite effects of TPT1-AS1 knockdown in pancreatic cancer cells, which demonstrated that miR-30a-5p was a mediator of TPT1-AS1 in pancreatic cancer. These data showed that TPT1-AS1 exerted oncogenic functions partly by sponging miR-30a-5p in pancreatic cancer.

Generally, as a ceRNA, the biological behavior of lncRNAs depends on the miRNA targets. To further predict miR-30a-5p targets in PDAC, bioinformatics databases and microarray analysis were used, which might mediate the TPT1-AS1/miR-30a-5p axis, and we predicted that ITGB3 could be a potential target for miR-30a-5p, which was confirmed by luciferase reporter assays. ITGB3 is a transmembrane receptor comprising two subunits, α and β, which belongs to the integrin family, and it is an important class of cell surface adhesion molecules in regulation of proliferation, invasion, and migration in breast, colorectal, and nasopharyngeal cancer.51–53 As expected, we found that ITGB3 expression was elevated in PDAC tissues compared with normal tissues, and high ITGB3 expression in PDAC patients was markedly associated with poor prognosis in PDAC patients. In addition, we found that ITGB3 levels in clinical samples were positively correlated with TPT1-AS1 and negatively correlated with miR-30a-5p. Notably, TPT1-AS1 positively regulated ITGB3 expression in pancreatic cancer cells, while miR-30a-5p showed an opposite regulatory effect. Finally, to investigate the roles of ITGB3 in TPT1-AS1, we performed rescue experiments, which demonstrated that ITGB3 knockdown could suppress the promotive effects on proliferation, migration, invasion, and EMT process induced by TPT1-AS1 overexpression, whereas restored ITGB3 eliminated the inhibitory effects induced by TPT1-AS1 knockdown. These findings suggested that ITGB3 mediated the promoting functions induced by TPT1-AS1/miR-30a-5p in PDAC.

It has also been shown that in tumor-repopulating cells, ITGB3 could mediate enhanced STAT3 activation, which was consistent with our previous findings30 (Figure 8B, Figure S14A). An increasing number of studies have demonstrated STAT3 could participate in the modulation of abnormal expression of lncRNAs in human malignancies,54 hence, we applied the JASPAR database (http://jaspar.genereg.net) and identified four major binding sites for STAT3 in the promoter region of TPT1-AS1. Previous studies have reported that IL-6 could promote tumor progression by activating STAT3; consistently, we found that upregulation of IL-6–activated STAT3 promoted high expression of TPT1-AS1 in pancreatic cancer cells. Finally, luciferase reporter assays demonstrated that upregulation of STAT3 led to an effective increase of TPT1-AS1 promoter activity. Overall, our results uncovered a reciprocal loop of TPT1-AS1 and ITGB3 which facilitated pancreatic cancer growth and development.
In summary, our study identified TPT1-AS1 as an oncogenic lncRNA in PDAC, which was significantly overexpressed in advanced pancreatic cancer and poorly differentiated pancreatic cancer. High TPT1-AS1 expression was associated with malignant clinical features and poor prognosis of PDAC patients. Functional experiments demonstrated that TPT1-AS1 could promote pancreatic cancer cell proliferation, invasion, migration, and EMT process in vitro and in vivo. Mechanistically, TPT1-AS1 directly bound to miR-30a-5p and served as a ceRNA to upregulate ITGB3 expression. In turn, ITGB3 could increase the expression of TPT1-AS1 via activating STAT3, thus forming a positive feedback loop. These findings demonstrated TPT1-AS1 could serve as an oncogene in pancreatic cancer, which might provide potential diagnostic and therapeutic targets for pancreatic cancer patients.

ACKNOWLEDGEMENTS
The authors are indebted to all the donors whose names were not included in the author list but who participated in our study.

DISCLOSURE
The authors declare that they have no competing interests.

DATA AVAILABILITY STATEMENT
All data generated or analyzed during this study are included in this published article and its Supplementary Information files.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
This study was approved by The First Affiliated Hospital of Harbin Medical University (Harbin, China), and written informed consent was obtained before any operation performed on patients.

CONSENT FOR PUBLICATION
We have obtained consents to publish this paper from all the participants of this study.

ORCID
Yongwei Wang https://orcid.org/0000-0001-9670-0922

REFERENCES
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33.
2. Thomas H. Pancreatic cancer: CYP3A5 contributes to PDAC chemoresistance. Nat Rev Gastroenterol Hepatol. 2016;13:188.
3. Dickson I. Pancreatic cancer: PDAC metastases show identifiable known driver gene mutations. Nat Rev Gastroenterol Hepatol. 2017;14:138.
4. Sahu A, Singhal U, Chinnaiyan AM. Long noncoding RNAs in cancer: from function to translation. Trends Cancer. 2015;1:93-109.
5. Abildgaard C, Do Canto LM, Steffensen KD, Rogatto SR. Long noncoding RNAs involved in resistance to chemotherapy in ovarian cancer. Front Oncol. 2019;9:1549.
6. Wang Y, Du L, Yang X, et al. A nomogram combining long noncoding RNA expression profiles and clinical factors predicts survival in patients with bladder cancer. Aging. 2020;12:2857-2879.
7. Spencer H, Sanders R, Boulberdaa M, et al. The LIN00961 transcript and its encoded micropeptide, small regulatory polypeptide of amino acid response, regulate endothelial cell function. Cardiovasc Res. 2020;116:1981-1994.
8. Pan S, Shen M, Zhou M, et al. Long noncoding RNA LINCO1111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Cell Death Dis. 2019;10:883.
9. Chen S, Chen JZ, Zhang JQ, et al. Silencing of long noncoding RNA LINCO0958 prevents tumor initiation of pancreatic cancer by acting as a sponge of microRNA-330-5p to down-regulate PAX8. Cancer Lett. 2019;446:49-61.
10. Yan J, Jia Y, Chen H, Chen W, Zhou X. Long non-coding RNA PXN-AS1 suppresses pancreatic cancer progression by acting as a competing endogenous RNA of miR-3064 to upregulate PIP4K2B expression. J Exp Clin Cancer Res. 2019;38:390.
11. Zeng Z, Xu FY, Zheng H, et al. LncRNA-MA2A2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1alpha. Theranostics. 2019;9:5298-5314.
12. Xiong G, Liu C, Yang G, et al. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. J Hematol Oncol. 2019;12:97.
13. Ou ZL, Zhang M, Ji LD, et al. Long noncoding RNA FEZF1-AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miR-142/HIF-1alpha and miR-133a/EGFR upon hypoxia/normoxia. J Cell Physiol. 2019. doi:10.1002/jcp.28188. Online ahead of print.
14. Xiao J, Lin L, Luo D, et al. Long noncoding RNA TRPM2-AS acts as a microRNA sponge of miR-612 to promote gastric cancer progression and radioresistance. Oncogenesis. 2020;9:29.
15. Lin Y, Jian Z, Jin H, et al. Long non-coding RNA DLGAP1-AS1 facilitates tumorigenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via the feedback loop of miR-26a/b-5p/IL-6/JAK2/STAT3 and Wnt/beta-catenin pathway. Cell Death Dis. 2020;11:34.
16. Zhang L, Ye F, Zuo Z, et al. Long noncoding RNA TPT1-AS1 promotes the progression and metastasis of colorectal cancer by upregulating the TPT1-mediated FAK and JAK-STAT3 signalling pathways. Aging. 2021;13:3779-3797.
17. Wu W, Gao H, Li X, et al. LncRNA TPT1-AS1 promotes tumorigenesis and metastasis in epithelial ovarian cancer by inducing TPT1 expression. Cancer Sci. 2019;110:1587-1598.
18. Jiang H, Huang G, Zhao N, et al. Long non-coding RNA TPT1-AS1 promotes cell growth and metastasis in cervical cancer via acting as a sponge for miR-324-5p. J Exp Clin Cancer Res. 2018;37:169.
19. Tang J, Huang F, Wang H, et al. Knockdown of TPT1-AS1 inhibits cell proliferation, cell cycle G1/S transition, and epithelial-mesenchymal transition in gastric cancer. Bosn J Basic Med Sci. 2021;21:39-46.
20. Aiello NM, Kang Y. Context-dependent EMT programs in cancer metastasis. J Exp Med. 2019;216:1016-1026.
21. Li N, Deng W, Ma J, et al. Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer. Med Oncol. 2015;32:433.
22. Hu H, Wang Y, Ding X, et al. Long non-coding RNA XLOC_000647 sensitizes pancreatic cancer cells to gemcitabine via acting as a sponge for miR-212-5p. Int J Oncol. 2018;53:527-535.
23. Li J, Ge J, Yang Y, Liu B, Zheng M, Shi R. Long non-coding RNA LINC00958 prevents tumor initiation of pancreatic cancer by upregulating the TPT1-mediated FAK and JAK-STAT3 signalling pathways. Theranostics. 2016;6:735-743.
24. Wang G, Pan J, Zhang L, Wei Y, Wang C. Long non-coding RNA CRNDE sponges miR-384 to promote proliferation and metastasis of pancreatic cancer cells through upregulating IRS1. Theranostics. 2019;9:5298-5314.
25. Chen S, Chen JZ, Zhang JQ, et al. Silencing of long noncoding RNA LINCO1111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Cell Death Dis. 2019;10:883.
26. Hua YQ, Zhu YD, Xie GQ, et al. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via up-regulating TWF1. *Aging (Albany, NY)*. 2019;11:8860-8878.

27. Xu DF, Wang LS, Zhou JH. Long noncoding RNA CASC2 suppresses pancreatic cancer cell growth and progression by regulating the miR24/MUC6 axis. *Int J Oncol*. 2020;56:494-507.

28. Li N, Yang G, Luo L, et al. LncRNA THAP9-AS1 promotes pancreatic ductal adenocarcinoma growth and leads to a poor outcome in cancer via sponging miR-484 and interacting with YAP. *Clin Cancer Res*. 2020;26:1736-1746.

29. Liu H, Liu S, Liu L, Ma R, Gao P. EGR1-mediated transcription of LncRNA THAP9-AS1 promotes pancreatic ductal adenocarcinoma growth and leads to a poor outcome in cancer via sponging miR-484 and interacting with YAP. *Clin Cancer Res*. 2020;26:1736-1746.

30. Li Y, Song Y, Li P, et al. Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-alpha-induced apoptosis in tumor-repopulating cells of melanoma. *J Immunother Cancer*. 2020;8(1):e000111.

31. Cheng J, Ma H, Yan M, Xing W. THAP9-AS1/miR-133b/FOX4 positive feedback loop facilitates the progression of esophageal squamous cell carcinoma. *Cell Death Dis*. 2021;12:401.

32. Zhang J-X, Chen Z-H, Chen D-L, et al. LINC01410-miR-532-NCF2-NF-kβ feedback loop promotes gastric cancer angiogenesis and metastasis. *Oncogene*. 2018;37:2660-2675.

33. Yao G, Chen K, Qin Y, et al. Long non-coding RNA JHDM1D-AS1 interacts with DHX15 protein to enhance non-small-cell lung cancer growth and metastasis. *Mol Ther Nucleic Acids*. 2019;18:831-840.

34. Chen B, Zhang Q, Wang X, et al. The lncRNA ENSG00000254041.1 promotes cell invasiveness and associates with poor prognosis of pancreatic ductal adenocarcinoma. *Aging (Albany, NY)*. 2020;12:3647-3661.

35. Hua Q, Mi B, Xu F, et al. Hypoxia-induced IncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1alpha axis. *Theranostics*. 2020;10:4762-4778.

36. Wang J, Yang S, Ji Q, et al. Long non-coding RNA EPIC1 promotes cell proliferation and motility and drug resistance in glioma. *Mol Ther Oncolytics*. 2020;17:130-137.

37. Xu S, Wang Q, Kang Y, et al. Long noncoding RNAs control the modulation of immune checkpoint molecules in cancer. *Cancer Immunol Res*. 2020;8:937-951.

38. Yang Q, Li K, Huang X, et al. LncRNA SLC7A11-AS1 promotes chemoresistance by blocking SCF(beta-TRCP)-mediated degradation of NRF2 in pancreatic cancer. *Mol Ther Nucleic Acids*. 2020;19:974-985.

39. Zhang B. Guizhi Fuling pills inhibit the proliferation, migration and invasion of human cutaneous malignant melanoma cells by regulating the molecular axis of LncRNA TPT1-AS1 / miR-671-5p. *Cell Mol Biol (Noisy-le-grand)*. 2020;66:148-154.

40. Huang Y, Zheng Y, Shao X, Shi L, Li G, Huang P. Long non-coding RNA TPT1-AS1 sensitizes breast cancer cell to paclitaxel and inhibits cell proliferation by miR-3156-5p/caspase 2 axis. *Hum Cell*. 2021;34:1244-1254.

41. Zhang J, Gao S, Zhang Y, et al. MiR-216a-5p inhibits tumorigenesis in pancreatic cancer by targeting TPT1/mTORC1 and is mediated by LINC01133. *Int J Biol Sci*. 2020;16:2612-2627.

42. Wang W, Hu W, Wang Y, et al. Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA. *Mol Cancer*. 2020;19:18.

43. Xu L, Wu Q, Yan H, et al. Long noncoding RNA KB-1460A1.5 inhibits glioma tumorigenesis via miR-130a-3p/TSC1/mTOR/YY1 feedback loop. *Cancer Lett*. 2021;525:33-45.

44. Harrandah A, Mora R, Chan E. Emerging microRNAs in cancer diagnosis, progression, and immune surveillance. *Cancer Lett*. 2018;438:126-132.

45. Pan Y, Tong S, Cui R, et al. Long non-coding MALAT1 functions as a competing endogenous RNA to regulate vimentin expression by sponging miR-30a-5p in hepatocellular carcinoma. *Cell Physiol Biochem*. 2018;50:108-120.

46. Ye YY, Mei JW, Xiang SS, et al. MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F2. *Cell Death Dis*. 2018;9:410.

47. Zhou L, Jia S, Ding G, et al. Down-regulation of miR-30a-5p is associated with poor prognosis and promotes chemoresistance of gemcitabine in pancreatic ductal adenocarcinoma. *J Cancer*. 2019;10:5031-5040.

48. Chen C, Tang J, Xu S, Zhang W, Jiang H. MiR-30a-5p inhibits proliferation and migration of lung squamous cell carcinoma cells by targeting FOXD1. *Biomed Res Int*. 2020;2020:2547902.

49. Li J, Zhao LM, Zhang C, et al. The lncRNA FEZF1-AS1 promotes the progression of colorectal cancer through regulating OTX1 and targeting miR-30a-5p. *Oncol Res*. 2020;28:51-63.

50. Li X, Liu J, Liu M, Xia C, Zhao Q, The Lnc LINC00461/miR-30a-5p facilitates progression and malignancy in non-small cell lung cancer via regulating ZEB2. *Cell Cycle*. 2020;19:825-836.

51. Wen S, Hou Y, Fu L, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin beta3-p38 MAPK signalling. *Cancer Lett*. 2019;442:320-332.

52. Zheng ZQ, Li ZX, Zhou GQ, et al. Long noncoding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and upregulate ITGB3. *Cancer Res*. 2019;79:4612-4626.

53. Wei W, Yang Y, Cai J, et al. MiR-30a-5p suppresses tumor metastasis of human colorectal cancer by targeting ITGB3. *Cell Physiol Biochem*. 2016;39:1165-1176.

54. Teng Y, Loveless R, Benson E, Sun L, Shull A, Shay C. SHOX2 cooperates with STAT3 to promote breast cancer metastasis through the transcriptional activation of WASF3. *J Exp Clin Cancer Res*. 2021;40:274.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

*How to cite this article:* Cheng C, Liu D, Liu Z, et al. Positive feedback regulation of IncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. *Cancer Sci*. 2022;113:2986-3001. doi:10.1111/cas.15388